Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
148 INR | +1.61% | +0.27% | +6.63% |
May. 14 | Jefferies Adjusts Piramal Pharma’s Price Target to INR180 From INR170, Keeps at Buy | MT |
May. 13 | Transcript : Piramal Pharma Limited, Q4 2024 Earnings Call, May 13, 2024 |
Sales 2024 | 81.71B 980M | Sales 2025 * | 92.17B 1.1B | Capitalization | 196B 2.35B |
---|---|---|---|---|---|
Net income 2024 | 178M 2.13M | Net income 2025 * | 2.32B 27.87M | EV / Sales 2024 | 2.09 x |
Net Debt 2024 * | 33.7B 404M | Net Debt 2025 * | 36.8B 441M | EV / Sales 2025 * | 2.53 x |
P/E ratio 2024 |
921
x | P/E ratio 2025 * |
83.5
x | Employees | 6,295 |
Yield 2024 * |
0.14% | Yield 2025 * |
0.2% | Free-Float | 26.82% |
Latest transcript on Piramal Pharma Limited
1 day | +1.61% | ||
1 week | +0.27% | ||
1 month | +3.06% | ||
3 months | +12.89% | ||
6 months | +17.31% | ||
Current year | +6.63% |
Managers | Title | Age | Since |
---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 46 | 20-03-03 |
Vivek Valsaraj
PSD | President | 51 | 20-06-09 |
Vinay Agrawal
COO | Chief Operating Officer | 60 | 20-04-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 43 | 21-01-03 | |
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | - |
Director/Board Member | 76 | 21-02-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 7 M€ | +5.36% | - | |
0.00% | 112 M€ | +4.61% | - | |
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 148 | +1.61% | 3,816,461 |
24-05-30 | 145.7 | -2.83% | 1,991,282 |
24-05-29 | 150 | -0.03% | 2,250,492 |
24-05-28 | 150 | +0.20% | 3,518,065 |
24-05-27 | 149.7 | +1.39% | 4,422,073 |
Delayed Quote NSE India S.E., May 31, 2024 at 07:43 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.63% | 2.35B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- PPLPHARMA Stock